Edit |   |
---|---|
Antigenic Specificity | CD283 (TLR3), Mouse |
Clone | 11F8 |
Host Species | Rat |
Reactive Species | mouse |
Isotype | IgG2a |
Format | allophycocyanin (APC) conjugate |
Size | 9 µg in 300 µL |
Concentration | 1:10 |
Applications | Intracellular flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD283 (TLR3) Antibody, anti-mouse, APC. Clone 11F8 recognizes CD283 antigen, which is also known as toll-like receptor 3 (TLR3). Toll-like receptors are a family of pattern recognition receptors that have evolved to detect components of foreign pathogens referred to as pathogen associated molecular patterns. TLR3 is a single-pass type I membrane protein expressed exclusively in intracellular vesicles, such as the endoplasmic reticulum (ER), endosomes, lysosomes, and endolysosomes, where it recognizes microbial dsRNA. Multiple cell types are known to express TLR3 including dendritic cells, keratinocytes, and neurons. TLR3 activates antiviral immune responses via the TRIF-dependent pathway and eventually through the production of type I interferon and inflammatory cytokines, suggesting that TLR3 has an essential role in the prevention of viral infection. |
Immunogen | n/a |
Other Names | TLR3 |
Gene, Accession # | Gene ID: 142980 |
Catalog # | 130-103-399 |
Price | $66 |
Order / More Info | CD283 (TLR3), Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Doyle, S. E. et al. (2003) Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol 170 (7): 3565-3571. | Alexopoulou, L. et al. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (6587): 732-738. | Applequist, S. E. et al. (2002) Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14 (9): 1065-1074. |